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There are many different and relatively discrete mech-
anisms leading to ventricular fibrillation. Therefore, any
single approach to prevention is likely to be unsuccessful,
particularly because the circumstances that finallycause
sudden cardiac death may not be present for more than
a short time before the onset of ventricular fibrillation.
It should not be surprising, therefore, that neither pri-
mary nor secondary prevention trials directed at cor-
recting risk factors for coronary heart disease have been
associated with a reduction in the incidence of sudden
cardiac death. More trials are needed in patients with
Trials established to prevent the development of a disease
are usually based on a clear hypothesis that modulation of
an apparently adverse influence might be beneficial. How-
ever, the adverse influences or risk factors relating to sudden
cardiac death are so nonspecific and their predictability in
a previously healthy person is so low that no trials are likely
to be conducted with the express purpose of determining
whether it is possible to reduce the incidence of sudden
cardiac death. Therefore, it appears to me there are only
two ways to examine whether there has been any material
change in the incidence of sudden cardiac death in recent
years. One is to appraise theresults of those major primary
and secondary prevention trials established with the inten-
tion of reducing coronary heart disease; the other is to ex-
amine trends in sudden cardiac death and case fatality rates.
Both are difficult undertakings.
Problems
A problem with the analysis of trials is that many do not
report sudden cardiac death as such or combine this entity
with fatal coronary heart disease or, even worse, report it
as a first or new" coronary event. " This merging of clinical
events with different biologic mechanisms as a single end
point for coronary heart disease is a matter for serious crit-
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unstable angina, in whom there is a relatively high in-
cidence of sudden cardiac death within a short period.
Methods of modulating catecholamine response, myo-
cardial vulnerability and thrombotic mechanisms re-
quire more formal testing. However, because the sen-
sitivity and specificityof prediction of those likely to die
suddenly are so poor, it may become necessary to accept
that the majority of sudden cardiac deaths is not yet
preventable and focus on continuing to improve cardio-
pulmonary resuscitation services.
(J Am Coll CardioI1985,'5:150B-154B)
icism, because any given intervention might be effective
against ventricular fibrillation, coronary thrombosis, myo-
cardial infarction or coronary spasm, but not against any
combination of these. Not only is the specificity of the
relation of the intervention to the end point diluted, but
exaggerated claims for benefit may result through the ad-
dition of numbers too small in themselves to show a sig-
nificant difference. Another problem is the small number
of cases of sudden cardiac death available for analysis,
although many of the trial populations are sizeable.
Several problems exist regarding interpretation oftrends
in sudden cardiac death rates and case fatality rates. First,
there is an inadequate reported data base. Second, defini-
tions are too loose to permit much certainty about the sud-
denness of the reported death. Third, there is an unknown
degree of dilution of presumed fatal sudden deaths from
coronary heart disease with deaths from other causes (mis-
diagnosis) and from unexplained causes.
Primary Prevention Trials
None of the coronary heart disease primary prevention
trials, whether aimed at reduction of hypercholesterolemia
in high risk men or at multiple risk factor intervention, has
led to a statistically significant reduction in sudden cardiac
death (Table I). Reconstruction of Table I in the form of
age-standardized annual or 5 year rates per 1,000 persons
at risk does not alter the negative findings. A possible ex-
ception is that the sudden cardiac death rates were signifi-
cantly lower in a high cholesterol subgroup of the Los
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Table 1. Sudden Cardiac Deaths and Nonsudden Coronary Heart Disease Deaths in Primary Prevention Trials
No. of
Sudden Cardiac Deaths Nonsudden CHD Deaths
Trials Intervention Subjects Intervention Control Intervention Control
High Cholesterol Intervention
Los Angeles Veterans Administration (1)* (1969) Diet 846 18 27 23 23
Helsinki Mental Hospital (7) (1972) Diet 922 (not stated)! 6 12
WHO Clofibrate (9) (1978) Clofibrate 10,627 23 17 36 34
LRC-CPPT (8) (1984) Cholestyramine 3,806 (not stated)t 30 38
Multiple Risk Intervention
Oslo (2) (1981) Cholesterol and 1,232 3 II 3 3
smoking
MRFlT (5) (1982) MUltiple 12,866 54 58 61 69
WHO MRFlT (27) (1983) Multiple 60,881 (not stated)! 83 64
All trials (% of study population) 91,180 98 113 241 240
(0.77%) (0.88%) (0.53%) (0.53%)
*Numbers in parentheses refer to reference numbers. tThe number of sudden cardiac deaths in these trials is contained within the nonsudden death
figures, and probably no more than half of the differences will be due to sudden cardiac deaths. CHD = coronary heart disease; LRC-CPPT = Lipid
Research Clinics Coronary Primary Prevention Tria); MRFlT = Multiple Risk Factor Intervention Trial; WHO = World Health Organization.
Angeles Veterans Trial (1) treated with a high polysaturated
fat diet.
There was a marginally favorable difference in the Oslo
Study (2). This was a trial of reducing serum cholesterol
and cigarette smoking in men with initial cholesterol levels
above the 90th percentile; although the main effect was
thought to be due to reduction in serum cholesterol, the
change in smoking might have accounted for 25% of the
difference in incidence of coronary heart disease and it is
impossible to apportion the small change in sudden cardiac
death rates to either interventions. Although the evidence
that quitting smoking is associated with a reduction in coro-
nary heart disease deaths (3), detailed information concern-
ing changes in sudden cardiac death rates has not apparently
been published, although it must surely have been recorded.
Primary prevention trials ofthe effects of lowering blood
pressure on coronary heart disease also do not provide in-
formation concerning changes in sudden cardiac death and
it was not possible, therefore, to include this information
in Table 1. Because the impact of decreasing high blood
pressure on all coronary heart disease deaths is unimpressive
and not significant (4), it is unlikely that a decrease in blood
pressure will have made any important impact on sudden
cardiac death rates. Results from two of the primary pre-
vention trials suggest the possibility that intervention to
decrease blood pressure may actually increase deaths due
to coronary heart disease and possibly sudden cardiac death.
In both trials diuretic drugs were used: in the Multiple Risk
Factor Intervention Trial (5) there was an excess of 11 (61%)
coronary heart disease deaths in men who were initially
hypertensive with an abnormal electrocardiogram compared
with the control group; in the Medical Research Council
mild to moderate hypertension trial (6), there was a statis-
tically significant excess of serious ventricular premature
beats in the treated ~roup.
It should be mentioned that the effect of intervention on
nonsudden coronary heart disease deaths in these seven
major primary prevention trials is also nil (Table 1). Trials
reporting favorable effects on incidence of coronary heart
disease achieve this either by adding nonfatal myocardial
infarct rates to coronary heart disease deaths (Los Angeles
Veterans Administration Study [1], Helsinki Mental Hos-
pital Study [7), the Oslo Study [2) and the Lipid Research
Clinics Coronary Primary Prevention Trial [8)) or by con-
sidering nonfatal infarction rates alone (World Health Or-
ganization Clofibrate Trial [9)). When a relatively precise
and hard end point such as cardiac death is analyzed, the
results are negative.
Secondary Prevention Trials
Myocardial infarction. The incidence of sudden Car-
diac death after myocardial infarction is higher than before
infarction, and it may be expected that the impact of inter-
vention might be more identifiable in patients with than in
those without prior infarction. However, this is only true
for beta-adrenergic blocking drugs (see following), and trials
aimed at lowering high cholesterol or blood pressure levels
have not been associated with reduction of sudden cardiac
death (Table 2).
The consistency in the effects of the beta-adrenergic
blockade secondary prevention trials (10-14) on sudden
cardiac death during the first year of administration of beta-
blocking agents, as well as a decrease in all deaths due to
coronary heart disease, is impressive (Table 3). Indeed, the
biggest contribution to the decrease in coronary heart disease
deaths in these trials was the decrease in sudden cardiac
death.
The use of sulfinpyrazone (15) is difficult to assess be-
cause the United States trial suggests a significant decrease
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Table 2. Sudden Cardiac Deaths in Secondary Prevention Trials After Myocardial Infarction
No. of
Sudden Cardiac Deaths
Trial Subjects Intervention (%) Control (%)
Coronary Drug Project
Dextrothyroxine (20)* (1972) 1,083 5.8 6.0
Clofibrate (21) (1975) 1,103 10.5 11.4
Niacin (21) (1975) 1,1l9 11.9 11.4
Controls 2,789
Sulfinpyrazone
United States (15) (1978) 1,475 1.6 3.6 P < 0.02
Italy (16) (1982) 727 3.0 2.5
Persantin-Aspirin
PARIS (28) (1980)
Persantin 810 3.7 4.4
Aspirin 810 5.6 4.4
Aspirin: AMIS (29) (1980)
< I hour 4,524 2.7 2.0
I to 24 hours 4,524 3.5 3.0
All trials (% of study population) 14,440 8.1% (554) 8.4% (575)
*Numbers in parentheses refer to reference numbers. AMIS = Aspirin Myocardial Infarction Study Group;
PARIS = Persantine-Aspirin Reinfarction Study Group.
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in sudden cardiac death and no change in nonfatal myo-
cardial infarction and the Italian trial (16) showed opposite
effects. Criticism of the design and conduct of the United
States sulfinpyrazone trial has been considerable.
Angina. Angina, without or with preceding myocardial
infarction, is associated with recurrent episodes of regional
myocardial ischemia and some of these may give rise to
circumstances that lead to reentrant arrhythmias. Sudden
cardiac death is most likely to occur in patients with unstable
angina and it is in such patients that prevention might be
expected to be most successful. Although sudden cardiac
death is not usually preceded by any clinical characteristics
that would permit the average doctor to diagnose incipient
clinical coronary disease (17), there are many documented
accounts-and it is quite common clinical experience-that
those who have died unexpectedly and suddenly have had
characteristic anginal symptoms for a few hours before their
death. Unfortunately, most persons dismiss, rationalize or
deny these symptoms as being of any significance. If the
public were better educated about these symptoms and more
alerted to their potential gravity, preventive measures might
be more effective in reducing sudden cardiac death because
reduction of acute thrombotic effects and reduction of myo-
cardial catecholamine activity would be expected, for sep-
arate reasons, to be associated with fewer reentrant
arrhythmias.
It is in patients with unstable angina that trials are most
needed. So far, there are few clear-cut data. The Veterans
Administration aspirin trial (18) produced a nearly statis-
tically significant reduction in cardiac deaths in 625 patients
with unstable angina over a 12week period, but the numbers
were not large enough to reach any conclusion for sudden
cardiac death. The use of intravenous beta-adrenergic block-
ade in patients admitted to a hospital with active myocardial
ischemia short of infarction has not yet been subjected to a
large enough formal clinical trial to determine the effect on
sudden cardiac death.
Anotherinsufficiently exploredarea is the effectofdrugs
in stable angina. The only trial that has been conducted in
reasonably large numbers is the Scottish and Newcastle
Table3. Effects of Beta-AdrenergicBlocking Agent Trials on Sudden Cardiac Death After Myocardial Infarction
No. of
Sudden Cardiac Deaths Nonsudden Cardiac Deaths
Trials Intervention Subjects Intervention Control p Value Intervention Control p Value
Multicenter International (10)* (1977) Practolol 3,038 30 52 <0.02 17 21 NS
Norwegian Multicenter (11) (1981) Timolol 1,884 47 95 <0.001 II 18 NS
BHAT (12) (1982) Propranolol 3,837 64 89 <0.05 55 75 NS
Swedish trial (13) (1982) Metoprolol 1,395 (not stated) 40 62 0.03
Norwegian Multicenter (14) (1982) Propranolol 560 IO 19 <0.10 10 6 NS
*Numbers in parentheses refer to reference numbers. BHAT = Beta-Blocker Heart Attack Trial Research Group.
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Table 4. Sudden Cardiac Death in Angina and
Myocardial Infarction*
First Clinical No. of
Percent of all Patients
Presentation Subjects Clofibrate Control p Value
Angina 689 2.7 (9)t 8.6 (31) <0.02
Myocardial infarction 818 5.0 (20) 7.5 (31) NS
*From the Scottish and Newcastle clofibrate trials, Dewar and Oliver
(19). tNumbers in parentheses refer to reference numbers.
Clofibrate study (19). This was established to determine
whether reduction of increased cholesterol levels in patients
with stable angina would be associated with a decrease in
coronary heart disease. However, clofibrate also has a pro-
found effect in decreasing plasma fibrinogen, and it seems
to me that the positive results (Table 4) are better explained
on this basis rather than by any effect on lowering choles-
terol, particularly because clofibrate did not have a signif-
icant effect in patients with previous myocardial infarction
either in this study or in the Coronary Drug Project (20,21).
Trends in Sudden Death and Case Fatality
Because of the lack of information available from death
certificates and the problems outlined earlier, there are no
adequate data on international or national trends on sudden
cardiac death. A useful source of data, however, is the
"prospective in retrospect" Rochester (Minnesota) study
(22). From that study it appears that there has been an
approximately 40% decrease in sudden unexpected deaths
from 1950 to 1975 in contrast to a 12% decrease in myo-
cardial infarction. The greatest change in frequency of sud-
den death occurred in those aged 70 years or more, and
there were no significant changes in frequency among mid-
dle-aged persons.
Three recent reports indicate that there has been a strik-
ing decrease in case fatality during the last 15 years. A
hospital records study (1969 to 1977) (23) showed a decrease
Neural Stimuli
in hospital case fatality rates in the United States from 26.5%
in 1969 to 18.8% in 1977 ( - 29%). In Rochester, Minnesota
(22), the case fatality rate decreased from 18% between
1965 and 1969 to 9.3% between 1970 and 1975. The Min-
nesota Heart Survey (24) showed a similar change with a
55% decrease in 1978 in comparison with the 1970 statistic
for persons resuscitated outside the hospital, which is prob-
ably the nearest one can get to data on sudden cardiac death.
Improvement in resuscitation rates in the emergency room
was less impressive, but overall the decrease in age-adjusted
death rate for acute myocardial infarction in the emergency
room and outside the hospital was approximately 37% for
men and 46% for women. These decreases in community
case fatality rates are, of course, in keeping with the re-
markable and impressive impact of improved cardiopul-
monary resuscitation in patients with ventricular fibrillation
(25,26).
Any consideration of the impact ofprevention on sudden
cardiac death must also take into account the benefits of
earlier and more accurate diagnosis through cardiovascular
investigative procedures and operations. The National Cen-
ter for Health Statistics (23) in the United States suggests
that these may have increased during the last decade by
29%. This figure is close to the reduction in case fatality
rates; although it is inappropriate to relate these too closely,
an increase by 55% in the use of pacemakers and an increase
in coronary artery bypass graft operations by 66% is bound
to have made some impact.
Future Prevention
Large clinical trials of the effects of primary prevention
on coronary heart disease have not shown a reduction in
sudden cardiac death. Similarly, secondary prevention trials
after myocardial infarction have been unyielding in relation
to sudden death. There is no really convincing evidence of
any spontaneous improvement in sudden cardiac death rates
since 1950, but case fatality rates have decreased in the
United States.
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Figure 1. Some mechanisms leading to sudden car-
diac death.
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More clinical trials of modulating the catecholamine re-
sponse or thrombotic mechanisms, or both, in patients with
unstable angina need to be established. Few have been con-
ducted and the results of none are clearly positive.
All clinical trials of the effects of treatment on sudden
cardiac death depend on improving the sensitivity and spec-
ificity of prediction of those likely to die suddenly in the
next few weeks. This problem may never be solved, because
the circumstances that lead to sudden cardiac death may not
be present even 5 minutes before the onset of ventricular
fibrillation. lit addition, the various mechanisms leading to
sudden cardiac death are so very different (Fig. 1) that any
single approach to prevention is unlikely to be successful.
I think, therefore, that we must accept that the majority
of sudden cardiac deaths will probably not be preventable
and concentrate on continuing to improve cardiopulmonary
resuscitation services and their extension far more widely
in the community.
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